Background
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease
caused by SARS-Cov-2. The leading cause in COVID-19 patients is
development of cytokine storm (1). Several cytokines such as IL-1,
TNF-α, IL-6, and interferon (IFN) have important role into the
development of COVID-19 associated cytokine storm (1). Several targeted
therapies such as anakinra, tocilizumab, and janus kinase (JAK)
inhibitors were found to be effective in patients with COVID-19
associated cytokine storm (2) (3) (4). However, there is limited
evidence with combination of targeted therapies in patients with
COVID-19.